Boston Scientific posted Q1 2026 sales of $5.2 billion and adjusted earnings near the top of its range, then cut full-year sales growth guidance from 10.5%–11.5% down to 7%–8.5% and trimmed adjusted EPS, citing weakness in three named businesses: Watchman, electrophysiology, and urology. The same week, Johnson & Johnson opened a head-to-head pulsed field ablation trial of Varipulse Pro against Boston Scientific’s Farapulse, Abbott released late-breaking PFA and conduction system pacing data at HRS 2026, and the Heart Rhythm Society published its first joint scientific statement on PFA with the European Heart Rhythm Association. The week is a concentrated picture of what happens to a category when a near-monopoly leader meets credible commercial competition.
Why Boston Scientific’s Watchman and EP Warning Resets the 2026 Outlook
Boston Scientific reported Q1 2026 revenue of $5.2 billion, an 11.6% reported gain, and net income of roughly $1.34 billion, according to MedTech Dive. CEO Mike Mahoney told investors the company was not proud of the guide-down but believed it was the right thing to do. The numbers behind that decision were that Watchman delivered $506 million in the quarter at 19.2% growth, but standalone Watchman procedures began declining in mid-February as practice patterns shifted, hospital capacity tightened, and EP physicians took on more of the procedure mix. Mid-teens growth is now the planning expectation for the franchise in 2026.
Electrophysiology grew 24% to $905 million in Q1, but the 2026 outlook for EP was reduced to roughly 10% growth as Boston Scientific acknowledged competitive share losses to Medtronic, Johnson & Johnson, and Abbott. Urology grew only 2%, with the company citing China value-based procurement, gaps in the core stone portfolio, and continued sacral neuromodulation disruption.
For founders, the relevant pattern is not specific to Boston Scientific. It is the speed at which a category-defining product loses pricing and volume durability once two or three credible commercial competitors clear regulatory and start publishing comparable outcomes. Watchman and Farapulse are both products that built a category. Both are now meeting the structural pressure that arrives with a multi-platform competitive set, and both are doing so on a timeline that internal planning models almost always underestimate.
J&J’s PERSIGMA Trial Pits Varipulse Pro Directly Against Farapulse
At HRS 2026 in Chicago, Johnson & Johnson’s Devi Nair featured one of the first cases from the PERSIGMA trial, a head-to-head comparison of the company’s Varipulse Pro PFA platform against Boston Scientific’s Farapulse, according to MassDevice. Direct head-to-head comparative trials between commercial competitors in EP have been rare. PERSIGMA signals that J&J is willing to commit to generating comparative data rather than relying on workflow differentiation.
For founders building in any device category where one company holds the majority share, the strategic implication is concrete. The playbook for taking share has moved from positioning around clinical workflow advantages to publishing the comparative evidence that makes the customer’s choice quantitative. If your competitive plan does not have a head-to-head evidence pathway in it, the absence is becoming visible faster.
Abbott’s HRS 2026 Late-Breaking Data Confirms a Four-Way PFA Race
Abbott presented four late-breaking presentations at HRS 2026, including six-month results from the FlexPulse IDE study of the TactiFlex Duo ablation catheter, the Volt CE Mark Extension Cohort data on posterior wall ablation, and first-in-human evaluations of the AVEIR conduction system pacing leadless pacemaker. The FlexPulse data reported 87% freedom from documented arrhythmias, a 98.3% safety profile with no major safety events, and 93.9% of patients not requiring a second ablation, according to Abbott’s announcement.
With Boston Scientific’s Farapulse, Medtronic’s PulseSelect, J&J’s Varipulse Pro, and Abbott’s Volt all now commercial or near-commercial, the PFA market has graduated from a one-leader category to a four-way platform race. Founders building enabling technology, mapping software, or workflow tools designed around a single platform partnership are now carrying a higher dependency risk than the same architecture carried twelve months ago.
HRS Publishes First Joint Scientific Statement on Pulsed Field Ablation
The Heart Rhythm Society and the European Heart Rhythm Association jointly released the 2026 HRS/EHRA Scientific Statement on Pulsed Field Ablation for Cardiac Arrhythmias. Scientific statements from these societies are how professional medicine signals that a technology has graduated from emerging innovation to clinical standard.
The statement carries two implications for founders. The first is that the PFA category now has formal clinical legitimacy across both regulatory regions, which compresses adoption timelines for credible entrants. The second is that the same legitimacy invites every credible competitor with an approved system into accounts that previously made a single-platform bet. The window for category-defining incumbency in PFA is closing on the schedule the joint statement just put on the calendar.
Dave’s take
The Boston Scientific guide-down is the kind of signal I tell every founder in a regulated category to study carefully. You can build a category and still lose volume and pricing durability faster than your operating plan assumes once two or three credible competitors clear regulatory and start generating comparable outcomes data. The question to ask about your own business is not whether you are the leader today, but whether the structural advantages you are counting on, regulatory position, evidence base, account relationships, training infrastructure, will compound or erode when the second and third commercial competitors arrive. If you do not know which of those advantages travel and which do not, you do not yet have a defensible position. You have a head start.
I’m here to help you scale.
Work With Dave